Guggenheim Capital LLC Arcellx, Inc. Transaction History
Guggenheim Capital LLC
- $13.3 Billion
- Q3 2025
A detailed history of Guggenheim Capital LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 8,172 shares of ACLX stock, worth $735,316. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,172
Previous 8,173
0.01%
Holding current value
$735,316
Previous $538,000
24.54%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ACLX
# of Institutions
226Shares Held
51.4MCall Options Held
85.4KPut Options Held
113K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.35MShares$572 Million0.32% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$418 Million12.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...